Calmer Co International Limited · ASX:CCO
Calmer Co International — Shareholder Meeting (November 2019)
19 slides from Calmer Co International's shareholder meeting presentation, Nov 28, 2019
Slide 1: Fiji Kava | Welcome to Fijiness
Slide 2: Disclaimer
DISCLAIMER This presentation and any Materials provided (materials) have been prepared by Fiji Kava Limited (Fiji Kava) and contain general information about Fiji Kava activities. By accepting the Materials and attending the Fiji Kava presentation, you agree to be bound by the below terms and condit
Slide 3: Fiji Kava milestones Dec 2018 to Nov 2019
MOU with Oborne Health Supplies “WE ARE MAKING PROGRESS IN Fiji Kava launches into USA on Amazon ESTABLISHING THE FOUNDATIONS Australian Prime Minister announces easing of Kava importation & commercial program into Australia FOR THE GROWTH OF FIJI KAVA” NZ Leading Pharmacy Group, Green Cross Health
Slide 4: Key Metrics
KEY METRICS FY19 FY20 YTD* (000’s) (000’s) KEY HIGHLIGHTS Revenue $182 $272 Investment in key personnel & capabilities Capital Raised $5,200 - Supply chain investment in company nucleus estate and Administration & Overheads $784 $985 planting of 31,000 plantlets Sales & Marketing $219 $393 Commissio
Slide 5: Growing Global Health Issues
GROWING GLOBAL HEALTH ISSUES
Slide 6: Complementary & Alternative Medicine Market to Exceed USD $210 Billion by 2026
COMPLEMENTARY & ALTERNATIVE MEDICINE MARKET, TO EXCEED USD $210 BILLION GLOBALLY BY 2026
Slide 7: Complementary & Alternative Medicine Market to Exceed USD $210 Billion by 2026
COMPLEMENTARY & ALTERNATIVE MEDICINE MARKET, TO EXCEED USD $210 BILLION GLOBALLY BY 2026 Provide a natural alternative to prescription medicines to promote sleep, soothe and calm the nerves, support muscle relaxation and relax the mind Anxiety Market Size – USD $15.60 Billion in 2018 and forecast to
Slide 8: Fiji Kava [ASX:FIJ]
FIJI KAVA [ASX:FIJ] NOBLE KAVA SUPPLY CHAIN EXCELLENCE MEDICINAL KAVA HEALTH & WELLNESS GROWING AVAILABILITY OF FIJIAN NOBLE KAVA COMPANY WHICH PRODUCES NATURAL ‘NOBLE KAVA’ PRODUCTS FOR THE COMPLEMENTARY AND ALTERNATIVE INNOVATION & PRODUCT DEVELOPMENT MEDICINE MARKET MEDICINAL BENEFITS
Slide 9: Supply Chain Excellence
SUP. LY CHAI EXCELLEN
Slide 10: Vertically Integrated, Sustainable and 100% Traceable Supply Chain
WE CONTINUE TO BUILD OUR VERTICALLY INTEGRATED, SUSTAINABLE AND 100% TRACEABLE SUPPLY CHAIN Fiji Kava only grow cultivars are of Noble variety – a superior form of kava We have established a nucleus estate* and the world’s first commercial kava tissue culture laboratory in Levuka, on the island of O
Slide 11: Noble Kava
OBLEKNVA :
Slide 12: First and Only Foreign Company with Fijian Government Approval
WE ARE THE FIRST AND ONLY FOREIGN COMPANY WITH APPROVAL FROM THE FIJIAN GOVERNMENT TO OPERATE IN THE NOBLE KAVA INDUSTRY Ranging in New World & Morris Medstorm Supermarkets in Fiji Pathway International agreement a leading Australian complementary medicine, personal care and pharmaceutical ingredien
Slide 13: Innovation & Product Development
Slide 14: Innovation to Provide Safe and Convenient Ways to Enjoy Noble Kava
INNOVATION TO PROVIDE CONSUMERS SAFE AND CONVENIENT WAYS TO ENJOY THE NATURAL BENEFITS OF FIJIAN NOBLE KAVA Proprietary kava profiling identifies specific kava cultivars targeting specific medical uses – insomnia, stress and anxiety and muscle relaxation Fiji Kava Noble Kava Extract Vegan Capsules F
Slide 15: Medicinal Benefits
Slide 16: Scientific and Traditional Evidence Supporting Therapeutic Benefits
PROMOTE SCIENTIFIC AND TRADITIONAL EVIDENCE SUPPORTING THERAPEUTIC BENEFITS TO HEALTH & WELLBEING For over 3,000 years, kava has been known for its relaxation and therapeutic benefits Medicinal benefits of kava are becoming widely recognised as a safer, natural alternative to prescription medicines
Slide 17: A Continued Measured Approach to Deliver Our Growth Strategy
A CONTINUED MEASURED APPROACH TO DELIVER OUR GROWTH STRATEGY The global complementary & alternative medicine market continues to grow driven by natural alternatives to growing social concerns Continue to build our supply chain scalability & capability whilst remaining agile in response to changing c
Slide 18: Investor Roadshow (November 2019)
Investor Roadshow (November 2019)
Slide 19: Appendix
APPENDIX Appendix 1 Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TMS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 – 2025. Kava Report 2003: In-Depth Investigation into EU
Calmer Co International — Shareholder Meeting (November 2019) on 6ix